Molecular mechanisms of micrometastasis of oral cancer and inhibition of metastasis by molecular target therapy
口腔癌微转移的分子机制及分子靶向治疗抑制转移
基本信息
- 批准号:14207091
- 负责人:
- 金额:$ 27.54万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (A)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In this study, we have attempted to clarify molecular mechanisms of micrometastasis of oral cancer in order to block metastasis targeting molecules related to micrometastasis. At first, we established two human oral squamous cell carcinoma (OSCC) cell lines and two human salivary gland cancer cell lines, which stably express green fluorescent protein (GFP) and have different potential of metastasis. Measurements of GFP strength make it possible to evaluate the in vitro invasiveness and in vivo lymph node micrometastasis and distant metastasis of tumor correctly and easily. Some molecules such as vascular endothelial growth factor (VEGF), chemokine receptor CXCR4, epithelial growth factor receptor (EGFR), matrix metalloproteinases (MMPs) and cytokine IL-8 were identified as candidate genes related to metastasis of OSCC by gene expression profile of human OSCC cell lines and OSCC tissues using human genome wide microarray. Further investigation of CXCR4,VEGF, EGFR and IL-8 revealed that … More CXCR4 and EGFR regulated the invasiveness and migration of OSCC cells respectively and VEGF regulated angiogenesis of OSCC tumor. In in vivo tumor model using athymic nude mice orthotopically inoculated with OSCC cells, the blockade of function of CXCR4 or EGFR and the inhibitors of angiogenesis markedly suppressed lymph node metastasis of tumor. Moreover, combination of radiotherapy enhanced their inhibitory effects. On the other hand, investigation of the mechanisms of metastasis in human salivary gland cancer cells suggested that hypoxia-inducible factor-1 (HIF-1) correlated with metastasis of human salivary gland cancer. Under hypoxic condition HIF-1 expression increased in human salivary gland cancer cells which have metastatic potential and hepatocyte growth factor (HGF) receptor/c-Met expression also increased. But in those which have no metastatic potential HIF-1 and c-Met did not increase under hypoxic condition. In addition to these results, many other novel genes related to metastasis of oral cancer were identified by this study. Less
在这项研究中,我们试图阐明口腔癌微含量的分子机制,以阻止靶向与微量含量相关的分子的转移。首先,我们建立了两个人口腔鳞状细胞癌(OSCC)细胞系和两个人类唾液腺癌细胞系,它们稳定地表达绿色荧光蛋白(GFP),并且具有不同的转移潜力。 GFP强度的测量使得正确,容易地评估体外浸润性和体内淋巴结微量和远处转移是可能的。某些分子,例如血管内皮生长因子(VEGF),趋化因子受体CXCR4,上皮生长因子受体(EGFR),基质金属蛋白酶(MMP)和细胞因子IL-8被鉴定为基因表达人类OSCC细胞和OSCC的OSCC的候选基因相关的候选基因和OSCC的候选基因。对CXCR4,VEGF,EGFR和IL-8的进一步研究表明,更多的CXCR4和EGFR调节OSCC细胞的侵入性和迁移以及VEGF调控OSCC肿瘤的血管生成。在体内肿瘤模型中,使用Anymic Nude小鼠原位接种了OSCC细胞,CXCR4或EGFR功能的阻断以及血管生成的抑制剂明显抑制了肿瘤的淋巴结转移。此外,放射疗法的组合增强了其抑制作用。另一方面,对人类唾液腺癌细胞转移机制的研究表明,缺氧诱导因子-1(HIF-1)与人类唾液腺癌的转移相关。在低氧条件下,HIF-1表达在人类唾液腺癌细胞中增加,具有转移性潜力和肝细胞生长因子(HGF)接收器/C-MET表达也有所增加。但是,在没有转移性潜在的HIF-1和C-MET的情况下,在低氧条件下不会增加。除这些结果外,这项研究还确定了许多与口腔癌转移相关的其他新型基因。较少的
项目成果
期刊论文数量(63)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Zen H, Nakashiro K, Shintani S, Sumida T, Aramoto T, Hamakawa H.: "Detection of circulating cancer cells in human oral squamous cell carcinoma."Int J Oncol. 23(3). 605-610 (2003)
Zen H、Nakashiro K、Shintani S、Sumida T、Aramoto T、Hamakawa H.:“人类口腔鳞状细胞癌中循环癌细胞的检测。”Int J Oncol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
S Shintani, C Li, M Mihara, N Terakado, K Nakashiro, Hamakawa H.: "Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA
S Shintani、C Li、M Mihara、N Terakado、K Nakashiro、Hamakawa H.:“通过与表皮生长因子受体酪氨酸激酶抑制剂吉非替尼(易瑞沙,ZD1839)联合治疗增强肿瘤放射反应,同时抑制 DNA
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Gefinitib ('Iressa', ZD1839), an eppidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines
Gefinitib(“Iressa”,ZD1839)是一种表皮生长因子受体酪氨酸激酶抑制剂,可上调 p27KIP1 并诱导口腔鳞状细胞癌细胞系中的 G1 期阻滞
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:S Shintani;C Li;M Mihara;J Yano;N Terakado;K Nakashiro;H Hamakawa
- 通讯作者:H Hamakawa
M.Mihara, S.Shintani, K.Nakashiro, H.Hamakawa: "Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells."Oral Oncology. 39(1). 49-55 (2003)
M.Mihara、S.Shintani、K.Nakashiro、H.Hamakawa:“Flavopiridol 是一种细胞周期蛋白依赖性激酶 (CDK) 抑制剂,通过调节口腔癌细胞中的 Bcl-x 来诱导细胞凋亡。”口腔肿瘤学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Lymph node metastasis of oral cancer visualised in live tissue by green fluorescent protein expression
通过绿色荧光蛋白表达在活组织中可视化口腔癌的淋巴结转移
- DOI:
- 发表时间:2002
- 期刊:
- 影响因子:0
- 作者:S.Shintani;M.Mihara;Y.Nakahara;T.Aida;T.Tachikawa;H.Hamakawa
- 通讯作者:H.Hamakawa
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HAMAKAWA Hiroyuki其他文献
HAMAKAWA Hiroyuki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HAMAKAWA Hiroyuki', 18)}}的其他基金
Clinical application of salivary microRNA to preemptive medicine for oral cancer
唾液microRNA在口腔癌抢救中的临床应用
- 批准号:
25670861 - 财政年份:2013
- 资助金额:
$ 27.54万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Expression and function of secreted microRNAs in oral cancer
分泌型microRNA在口腔癌中的表达和功能
- 批准号:
23659947 - 财政年份:2011
- 资助金额:
$ 27.54万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Personalized immunochemotherapy for oral cancer basedon the genetic diagnosis
基于基因诊断的口腔癌个体化免疫化疗
- 批准号:
22390386 - 财政年份:2010
- 资助金额:
$ 27.54万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Personalized medicine for oral cancer based on the bioinformatics
基于生物信息学的口腔癌个体化医疗
- 批准号:
17209063 - 财政年份:2005
- 资助金额:
$ 27.54万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Analysis of micrometastasis using GFP-expressed metastasis model of oral cancer and inhibition of metastasis by new anti-tumor drugs
GFP表达的口腔癌转移模型分析微转移及新型抗肿瘤药物抑制转移
- 批准号:
13557178 - 财政年份:2001
- 资助金额:
$ 27.54万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Genetic diagnosis of micrometastasis in oral cancer
口腔癌微转移的基因诊断
- 批准号:
10470434 - 财政年份:1998
- 资助金额:
$ 27.54万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
STUDY ON TUMOR MARKER OF SALIVARY GLAND
唾液腺肿瘤标志物的研究
- 批准号:
07672048 - 财政年份:1995
- 资助金额:
$ 27.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
EGLN3羟化酶通过调控巨噬细胞重编程促进肺癌细胞EMT及转移的机制研究
- 批准号:82373030
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于荧光共振能量转移及指示剂置换法策略纳米组装体比率荧光识别三磷酸腺苷
- 批准号:22361028
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
RNA甲基化转移酶METTL7B介导lncRNA-MIR22HG的m6A修饰促进脑缺血再灌注损伤的机制研究
- 批准号:82301476
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
海洋来源二倍半萜MHO7靶向整合素β8/TGF-β轴调控EMT抑制三阴性乳腺癌转移的作用机制研究
- 批准号:82304550
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Structural-Transcriptional Relationships that Improve Y537S Estrogen Receptor Antagonism
改善 Y537S 雌激素受体拮抗作用的结构转录关系
- 批准号:
10636229 - 财政年份:2023
- 资助金额:
$ 27.54万 - 项目类别:
Employing Novel Primary Mouse Models of Head and Neck Cancer to Overcome Chemoradiation Resistance
采用新型头颈癌原发小鼠模型来克服放化疗耐药性
- 批准号:
10918580 - 财政年份:2023
- 资助金额:
$ 27.54万 - 项目类别:
System-Level Analyses of Multi-Omics Data to Reveal Mechanisms of Head & Neck Cancer
多组学数据的系统级分析揭示头部机制
- 批准号:
10593974 - 财政年份:2022
- 资助金额:
$ 27.54万 - 项目类别:
Fingolimod and Ozanimod for the treatment and prevention of chemobrain
芬戈莫德和奥扎尼莫德用于治疗和预防化疗脑
- 批准号:
10696244 - 财政年份:2022
- 资助金额:
$ 27.54万 - 项目类别:
Phenotypic marker-guided development of selective antimetastasis therapeutic leads
表型标记引导选择性抗转移治疗先导药物的开发
- 批准号:
10650784 - 财政年份:2022
- 资助金额:
$ 27.54万 - 项目类别: